#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Adipocytokines as possible etiopathogenetic mechanisms leading to a higher incidence of autoimmune thyroiditis in patients with type 2 diabetes mellitus


Authors: Štefan Sotak 1;  Zbynek Schroner 2;  Ivica Lazúrová 1;  Marek Felš Ci 1;  Darina Petrášová 3;  Izabela Bertková 4;  Miriam Mitníková 5;  Jozefína Petrovičová 6
Authors place of work: I. interná klinika LF UPJŠ a UNLP Košice 1;  IV. interná klinika LF UPJŠ a UNLP Košice 2;  Laboratórium výskumných biomodelov LF UPJŠ v Košiciach 3;  Ústav experimentálnej medicíny LF UPJŠ v Košiciach 4;  Oddelenie laboratórnej medicíny UNLP Košice 5;  Ústav lekárskej informatiky LF UPJŠ v Košiciach 6
Published in the journal: Diab Obez 2019; 19(38): 103-109
Category: Reviews

Summary

Introduction: Autoimmune thyroiditis (AIT) and type 2 diabetes mellitus (DM) are the most common endocrinological diseases worldwide. Relationship between type 1 DM and AIT is well-known and described. Relation between these diseases explains several hypotheses. One of them is influence of some adipocytokines.

Objective: This study evaluated relationship between three adipocytokines (adiponectin, resistin, visfatin) and thyroidal status in patients with type 2 DM and AIT compared to control group (CG).

Material and methods: The group consisted of four subgroups: patients with type 2 DM without thyreopathies (n = 45), patients with AIT on substitution therapy without diabetes and prediabetes (n = 37), patients with type 2 DM and AIT on substitution therapy (n = 28) and healthy subjects as a CG (n = 34). We investigated parameters of thyroid and glycid metabolism and levels of three adipocytokines by venous blood-letting.

Results: We did not find statistically significant differences of adiponectine, resistin and visfatin levels between individual groups. We found moderate negative correlation between visfatin and fasting glucose levels (r = -0.35, p = 0.03) in patients with AIT without type 2. Conclusion: Our results are consistent with several studies, which do not find any relationship between thyropathies and adipocytokines.

Keywords:

adipocytokines – Adiponectin – autoimmune thyroiditis – resistin – type 2 diabetes mellitus – visfatin


Zdroje
  1. Schroner Z, Lazúrová I, Petrovičová J. Autoimmune thyroid diseases in patients with diabetes mellitus. Bratisl Lek Listy 2008; 109(3): 125–129.
  2. Kresser C. The Role of Vitamin D Deficiency in Thyroid Disorders 2010. [online]. [cit 20–04–2015]. Dostupné z www: <http://chriskresser.com/the-role-of-vitamin-d-deficiency-in-thyroid-disorders/>.
  3. Itariu BK, Stulnig TM. Autoimmune Aspects of Type 2 Diabetes Mellitus – A Mini Review. Gerontology 2014; 60(3): 189–196. Dostupné z DOI: <http://dx.doi.org/10.1159/000356747>.
  4. Gierach M, Gierach J, Skowrońska A et al. Hashimoto’s thyroiditis and carbohydrate metabolism disorders in patients hospitalized in the Department of Endocrinology and Diabetology of Ludwik Rydygier Collegium Medicum in Bydgoszcz between 2001 and 2010. Endokrynol Pol 2012; 63(1): 14–17.
  5. Cinar N, Gurlek A. Association between novel adipocytokines adiponectin, vaspin, visfatin, and thyroid: An experimental and clinical update. Endocr Connect 2013; 2(4): R30-R38. Dostupné z DOI: <http://dx.doi.org/10.1530/EC-13–0061>.
  6. Misra A, Vikram NK. Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition 2003; 19(5): 457–466. Dostupné z DOI: <http://dx.doi.org/10.1016/s0899–9007(02)01003–1>.
  7. Ahima RS, Qi Y, Singhal NS et al. Brain adipocytokine action and metabolic regulation. Diabetes 2006; 5(Suppl 2): S145-S154. Dostupné z DOI: <http://dx.doi.org/10.2337/db06-s018>.
  8. Fernández-Real JM, López-Bermejo A, Casamitjana R et al. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003; 88(6): 2714–2718. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2002–021583>.
  9. Cabanelas A, Cordeiro A, Santos Almeida NA et al. Effect of triiodothyronine on adiponectin expression and leptin release by white adipose tissue of normal rats. Horm Metab Res 2010; 42(4): 254–260. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0029–1246118>.
  10. Stumvoll M, Häring H. Resistin and Adiponectin – of Mice and Men. Obes Res 2002; 10(11): 1197–1199. Dostupné z DOI: <http://dx.doi.org/10.1038/oby.2002.162>.
  11. Nogueiras R, Gualillo O, Caminos JE et al. Regulation of resistin by gonadal, thyroid hormone, and nutritional status. Obes Res 2003; 11(3): 408–414. Dostupné z DOI: <http://dx.doi.org/10.1038/oby.2003.55>.
  12. Samal B, Sun Y, Stearns G et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14(2): 1431–1437. Dostupné z DOI: <http://dx.doi.org/10.1128/mcb.14.2.1431>.
  13. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178(3): 1748–1758. Dostupné z DOI: <http://dx.doi.org/10.4049/jimmunol.178.3.1748>.
  14. Iglesias P, Alvarez Fidalgo P, Codoceo R et al. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2003; 59(5): 621–629. Dostupné z DOI: <http://dx.doi.org/10.1046/j.1365–2265.2003.01897.x>.
  15. Santini F, Marsili A, Mammoli C et al. Serum concentrations of adiponectin and leptin in patients with thyroid dysfunctions. J Endocrinol Invest 2004; 27(2):RC5–7. Dostupné z DOI: <http://doi 10.1007/BF03346252>.
  16. Altinova AE, Törüner FB, Aktürk M et al. Adiponectin levels and cardiovascular risk factors in hypothyroidism and hyperthyroidism. Clin Endocrinol (Oxf) 2006; 65(4): 530–535. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2006.02628.x>.
  17. Iglesias P, Díez JJ. Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine 2007; 40(2): 61–70. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cyto.2007.10.001>.
  18. Siemińska L, Wojciechowska C, Kos-Kudła B et al. Serum concentrations of leptin, adiponectin, and interleukin-6 in postmenopausal women with Hashimoto’s thyroiditis. Endokrynol Pol 2010; 61(1): 112–116.
  19. Kaplan O, Uzum AK, Aral H et al. Unchanged serum adipokine concentrations in the setting of short-term thyroidectomy-induced hypothyroidism. Endocr Pract 2012; 18(6): 887–893. Dostupné z DOI: <http://dx.doi.org/10.4158/EP12001.OR>.
  20. Yildiz BO, Aksoy DY, Harmanci A et al. Effects of L-thyroxine therapy on circulating leptin and adiponectin levels in subclinical hypothyroidism: a prospective study. Arch Med Res 2013; 44(4): 317–320. Dostupné z DOI: <http://doi 10.1016/j.arcmed.2013.04.010>.
  21. Soriguer F, Valdes S, Morcillo S et al. Thyroid hormone levels predict the change in body weight: a prosp1ective study. Eur J Clin Invest 2011; 41(11): 1202–1209. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2362.2011.02526.x>.
  22. Ozcelik F, Yuksel C, Arslan E et al. Relationship between visceral adipose tissue and adiponectin, inflammatory markers and thyroid hormones in obese males with hepatosteatosis and insulin resistance. Arch Med Res 2013; 44(4): 273–280. Dostupné z DOI: <http://dx.doi.org/10.1016/j.arcmed.2013.04.001>.
  23. Krassas GE, Pontikides N, Loustis K et al. Resistin levels are normal in hypothyroidism and remain unchanged after attainment of euthyroidism: relationship with insulin levels and anthropometric parameters. J Endocrinol Invest 2006; 29(7): 606–612. Dostupné z DOI: <http://dx.doi.org/10.1007/BF03344159>.
  24. Ziora KT, Oswiecimska JM, Swietochowska E et al. Assessment of serum levels resistin in girls with anorexia nervosa. Part II. Relationships between serum levels of resistin and thyroid, adrenal and gonadal hormones. Neuro Endocrinol Lett 2011; 32(5): 697–703.
  25. Caixàs A, Tirado R, Vendrell J et al. Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters. Clin Endocrinol (Oxf) 2009; 71(5): 733–738. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2009.03546.x>.
  26. Han J, Zhang TO, Xiao WH et al. Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations. Chin Med J (Engl) 2012; 125(5): 874–881.
  27. Guzel S, Seven A, Guzel EC et al. Visfatin, Leptin, and TNF-α: Interrelated Adipokines in Insulin-Resistant Clinical and Subclinical Hypothyroidism. Endocr Res 2013; 38(3):184–194. Dostupné z DOI: <http://dx.doi.org/10.3109/07435800.2012.760588>.
  28. Ozkaya M, Sahin M, Cakal E et al. Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. J Endocrinol Invest 2009; 32(5): 435–439. Dostupné z DOI: <http://dx.doi.org/10.3275/6296>.
Štítky
Diabetology Obesitology
Článek Editorial

Článok vyšiel v časopise

Diabetes and obesity

Číslo 38

2019 Číslo 38
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#